China successfully completes the country#s first human implantation of a retrievable transcatheter aortic valve

Food and Healthcare Press Releases Wednesday November 29, 2017 08:54
HANGZHOU, China--29 Nov--PRNewswire/InfoQuest
  • The success of the procedure unleashes a new era for retrievable interventional cardiac valve technology in China
The first human implantation of the VenusA Plus retrievable valve system was completed successfully at the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU) on November 23, 2017.
https://photos.prnasia.com/prnvar/20171124/2000223-1

Prof. Wang Jian'an, president of SAHZU, announced that China has completed its first successful human implantation of a retrievable transcatheter aortic valve. It marks another milestone for Venus Medtech, becoming China's first company capable of providing a retrievable interventional cardiac valve system.

The 76-year-old female patient who was operated on using the system had been diagnosed with severe aortic valve stenosis and defined as a high-risk surgical patient. The heart team discussed and defined the patient's anatomical features as a bicuspid aortic valve and asymmetric calcification, which raised the risk of dislocation during the valve implantation. They were of the opinion that the retrievable system would be the best fit for the patient.

The retrievable system allows the valve to withdraw and reposition after release, avoiding adverse events as a result of a poor implant position and mismatch of the implanted valve, including valve translocation, severe paravalvular leakage, a negative impact on the bicuspid aortic valve and high degree atrioventricular block caused by conduction bundle compression. The system also reduces the complexity of the procedure, which, in turn, helps to promote the adoption and application of TAVR technology.

"SAHZU's medical team has been closely working with Zhejiang Province's Cardiac Valve Research Institute and Venus Medtech's R&D team to study, develop and produce the heart valve products. The collaboration began with the VenusA-Valve and has led to the success for VenusA Plus," professor Wang added. "The product is a next-generation TAVR valve that delivers good performance in terms of release, retrievable stability, controllability and passing ability, thus offering great potential when it comes to clinical applications."

The successful human implantation of VenusA Plus took place just four months after the launch of China's first TAVR valve VenusA-Valve. "Venus Medtech has continuously achieved technological breakthroughs," explained Venus Medtech CEO Zi Zhenjun. "We plan to roll out more innovative products going forward, demonstrating the company's strong competence in innovation and its ongoing commitment to serving patients."

Photo - https://photos.prnasia.com/prnh/20171124/2000223-1

Latest Press Release

Whisk#s AI-Powered Culinary Coach Named as Winner of Ascensia Diabetes Challenge

Today, at the American Diabetes Association's 78th Scientific Sessions in Orlando, Florida, Ascensia Diabetes Care has revealed that UK-based Whisk have been selected as the winner of the Ascensia Diabetes Challenge, a global innovation competition that...

Significant Blood Sugar Improvement With Xultophy(R) Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Adults with type 2 diabetes treated with Xultophy(R) (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy(R) (insulin degludec and liraglutide...

Tresiba(R) Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba(R) (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)...

Ozempic(R) Provided Greater Weight Reductions for Adults With a Baseline BMI ?25kg/m2 Than Those With Lower Baseline BMI 25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Ozempic(R) (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults...

Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated...

Related Topics